Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma (NCT05559879)
A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma
🩺 Plain-English Summary (8th-Grade Level)
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen presentation. In this study, Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic drug) will be admnistered as a combination to patients with recurrent gynecologic carcinosarcoma.
Who can join: Review the eligibility criteria below.
Location: O'Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- O'Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama
📞 Contact the Study Coordinator
Phone: (205) 934-4793
Email: mdtoboni@uabmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gynecologic Cancer
- Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer — New Brunswick, New Jersey
- Patient Related Outcomes for Gynecologic Radiation Oncology — Chapel Hill, North Carolina
- Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer — Boston, Massachusetts
- Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention — Houston, Texas
- Impact of Cultural and Linguistic Backgrounds on Patient Care and Experience of Women With Gynecologic Malignancies — Toronto, Ontario
- Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer — Minneapolis, Minnesota
Explore by condition: All Gynecologic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.